

Bedeutung thrombophiler Risikofaktoren für das Erst- und Rezidivthromboserisiko

- 1) Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. *Thromb.Haemost.* 1995;74:449-453.
- 2) Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. *Seminars in Hematology* 1997;34:171-187.
- 3) Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High-Risk of Thrombosis in Patients Homozygous for Factor-V Leiden (Activated Protein-C Resistance). *Blood* 1995;85:1504-1508.
- 4) Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. *Thromb.Haemost.* 2001;86:809-816.
- 5) Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 1996;88:3698-3703.
- 6) Junker R, Nowak-Göttl. The prothrombin G20210A mutation - a common cause of thrombophilia? *J.Lab.Med.* 1998
- 7) Ferraresi P, Marchetti G, Legnani C et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. *Arterioscler.Thromb.Vasc.Biol.* 1997;17:2418-2422.
- 8) Corral J, Gonzalez-Conejero R, Lozano ML et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. *Br.J.Haematol.* 1997;99:304-307.
- 9) Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. *Arteriosclerosis Thrombosis and Vascular Biology* 1997;17:2875-2879.
- 10) Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. *Thromb.Haemost.* 1997;78:1430-1433.
- 11) Hillarp A, Zoller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. *Thromb.Haemost.* 1997;78:990-992.
- 12) Margaglione M, D'Andrea G, d'Addetta M et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV leiden and the prothrombin A(20210) mutation. *Thrombosis and Haemostasis* 1998;79:907-911.
- 13) Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet* 1999;353:1453-1457.
- 14) Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated Protein-C Resistance As An Additional Risk Factor for Thrombosis in Protein C-Deficient Families. *Blood* 1994;84:1031-1035.
- 15) Tait RC, Walker ID, Perry DJ et al. Prevalence of Antithrombin Deficiency in the Healthy Population. *British Journal of Haematology* 1994;87:106-112.
- 16) Koster T, Rosendaal FR, Briet E et al. Protein-C Deficiency in A Controlled Series of Unselected Outpatients - An Infrequent But Clear Risk Factor for Venous Thrombosis (Leiden Thrombophilia Study). *Blood* 1995;85:2756-2761.
- 17) Faioni EM, Valsecchi C, Palla A et al. Free protein S deficiency is a risk factor for venous thrombosis. *Thrombosis and Haemostasis* 1997;78:1343-1346.
- 18) Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *Journal of Thrombosis and Haemostasis* 2006;4:295-306.
- 19) Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. *Blood* 2007;109:422-430.
- 20) Galli M. Antiphospholipid syndrome: Association between laboratory tests and clinical practice. *Pathophysiology of Haemostasis and Thrombosis* 2003;33:249-255.



- 21) Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood* 2003;101:1827-1832.
- 22) Ortel TL. Thrombosis and the Antiphospholipid Syndrome. *Hematology* 2005;462-468.
- 23) Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome - Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis and Rheumatism* 2002;46:1019-1027.
- 24) Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period - A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine* 2003;82:299-308.
- 25) Levine JS, Branch DW, Rauch J. Medical progress: The antiphospholipid syndrome. *New England Journal of Medicine* 2002;346:752-763.
- 26) Zotz RB, Sucker C, Gerhardt A. Thrombophilia in pregnancy Venous thromboembolism, fetal loss, preeclampsia, intrauterine growth restriction. *Hamostaseologie* 2008;28:455-464.
- 27) Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133:844S-886S.
- 28) Zotz RB, Gerhardt A, Segendorf H, Scharf RE. Significance of hereditary risk factors in patients with spontaneous recurrent thromboembolism [abstract]. *Angiology* 2001;20:58-59.
- 29) Schulman S, Rhedin AS, Lindmarker P et al. A Comparison of 6 Weeks with 6 Months of Oral Anticoagulant-Therapy After A First Episode of Venous Thromboembolism. *New England Journal of Medicine* 1995;332:1661-1665.
- 30) Levine MN, Hirsh J, Gent M et al. Optimal Duration of Oral Anticoagulant-Therapy - A Randomized Trial Comparing 4 Weeks with 3 Months of Warfarin in Patients with Proximal Deep-Vein Thrombosis. *Thrombosis and Haemostasis* 1995;74:606-611.
- 31) Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. *New England Journal of Medicine* 1997;336:393-398.
- 32) Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *New England Journal of Medicine* 1999;340:901-907.
- 33) Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. *New England Journal of Medicine* 2001;345:165-169.
- 34) Palareti G, Legnani C, Cosmi B et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. *Thrombosis and Haemostasis* 2002;87:7-12.
- 35) Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Annals of Internal Medicine* 2003;139:19-25.
- 36) Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003;362:523-526.
- 37) Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. *Circulation* 2003;108:313-318.
- 38) Kyrle PA, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. *New England Journal of Medicine* 2004;350:2558-2563.
- 39) Sudlow MF, Campbell IA, Angel JH et al. Optimum Duration of Anticoagulation for Deep-Vein Thrombosis and Pulmonary-Embolism. *Lancet* 1992;340:873-876.
- 40) Prandoni P, Lensing AWA, Buller HR et al. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. *New England Journal of Medicine* 1992;327:1128-1133.
- 41) Pini M, Aiello S, Manotti C et al. Low-Molecular-Weight Heparin Versus Warfarin in the Prevention of Recurrences After Deep-Vein Thrombosis. *Thrombosis and Haemostasis* 1994;72:191-197.





- 42) Pinede L, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. *Circulation* 2001;103:2453-2460.
- 43) Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *New England Journal of Medicine* 2003;348:1425-1434.
- 44) Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. *Archives of Internal Medicine* 2000;160:761-768.
- 45) Spiezia L, Bernardi E, Tormene D et al. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. *Thrombosis and Haemostasis* 2003;90:964-966.
- 46) Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. *Thrombosis and Haemostasis* 2000;84:805-810.
- 47) Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism - A population-based case-control study. *Archives of Internal Medicine* 2000;160:809-815.
- 48) Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood* 2002;100:3484-3488.
- 49) vandenBelt AGM, Sanson BJ, Simioni P et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. *Archives of Internal Medicine* 1997;157:2227-2232.
- 50) Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *New England Journal of Medicine* 2003;349:1133-1138.
- 51) Simioni P, Prandoni P, Lensing AWA et al. The risk of recurrent venous thromboembolism in patients with an Arg(506)->Gln mutation in the gene for factor V (factor V Leiden). *New England Journal of Medicine* 1997;336:399-403.
- 52) Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. *New England Journal of Medicine* 2000;343:457-462.
- 53) Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. *American Journal of Medicine* 1998;104:332-338.
- 54) Khamashta MA, Cuadrado MJ, Mujic F et al. The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome. *New England Journal of Medicine* 1995;332:993-997.
- 55) Prandoni P, Lensing AWA, Prins MH et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. *Annals of Internal Medicine* 2002;137:955-960.
- 56) Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. *Jama-Journal of the American Medical Association* 2003;290:1071-1074.
- 57) De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. *New England Journal of Medicine* 1999;341:801-806.
- 58) Piovella F, Crippa L, Barone M et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. *Haematologica* 2002;87:515-522.
- 59) Kearon C, Ginsberg JS, Kovacs MJ et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *New England Journal of Medicine* 2003;349:631-639.
- 60) Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. *Journal of Internal Medicine* 2000;247:601-606.
- 61) Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis. *Annals of Internal Medicine* 2003;139:893-900.
- 62) Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment. *Chest* 2004;126:287S-310S.





- 63) Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *American Journal of Medicine* 1998;105:91-99.
- 64) Hull R, Hirsh J, Jay R et al. Different Intensities of Oral Anticoagulant-Therapy in the Treatment of Proximal-Vein Thrombosis. *New England Journal of Medicine* 1982;307:1676-1681.
- 65) Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. *Lancet* 1988;1:1242-1245.
- 66) Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. *N.Engl.J.Med.* 1990;322:428-432.
- 67) Altman R, Rouvier J, Gurfinkel E et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. *J.Thorac.Cardiovasc.Surg.* 1991;101:427-431.
- 68) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann.Neurol.* 1997;42:857-865.
- 69) Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N.Engl.J.Med.* 1995;333:11-17.
- 70) Hylek EM, Singer DE. Risk-Factors For Intracranial Hemorrhage in Outpatients Taking Warfarin. *Annals of Internal Medicine* 1994;120:897-902.
- 71) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet* 1996;348:633-638.
- 72) Fihn SD, McDonnell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. *Ann.Intern.Med.* 1993;118:511-520.
- 73) Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial. *Annals of Internal Medicine* 2000;133:687-695.
- 74) Fuster V, Califf RM, Chesebro JH et al. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997;350:389-396.
- 75) Meade TW, Wilkes HC, Kelleher CC et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;351:233-241.
- 76) Fiore LD, Ezekowitz MD, Brophy MT et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002;105:557-563.
- 77) Johnsen SP, Sorensen HT, Mellekjoer L et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. *Thromb.Haemost.* 2001;86:563-568.
- 78) Knijff-Dutmer EA, Schut GA, Van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. *Ann.Pharmacother.* 2003;37:12-16.
- 79) Mellekjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. *Br.J.Clin.Pharmacol.* 2002;53:173-181.
- 80) Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease. *Chest* 2008;133:454S-545S.
- 81) Seligsohn U, Lubetsky A. Medical progress: Genetic susceptibility to venous thrombosis. *New England Journal of Medicine* 2001;344:1222-1231.
- 82) Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of Clotting Factor-VIII in Effect of Von-Willebrand-Factor on Occurrence of Deep-Vein Thrombosis. *Lancet* 1995;345:152-155.
- 83) Wahl DG, Guillemin F, de Maistre E et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. *Lupus* 1998;7:15-22.





- 84) Oger E, Lacut K, Le Gal G et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. *Journal of Thrombosis and Haemostasis* 2006;4:793-799.
- 85) Ridker PM, Miletich JP, Stampfer MJ et al. Factor-V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. *Circulation* 1995;92:2800-2802.
- 86) Lindmarker P, Schulman S, Sten-Linder M et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. *Thrombosis and Haemostasis* 1999;81:684-689.
- 87) Eichinger S, Weltermann A, Mannhalter C et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. *Arch.Intern.Med.* 2002;162:2357-2360.
- 88) Segendorf H, Zotz RB, Gerhardt A, Pilch J, Scharf RE. Independent risk factor of recurrent venous thromboembolism in multivariate statistical analysis [abstract]. *Annals of Hematology* 2000;79:V201b.
- 89) Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. *N.Engl.J.Med.* 2000;342:374-380.
- 90) Mcrae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. *Lancet* 2006;368:371-378.
- 91) Kearon C. Long-term management of patients after venous thromboembolism. *Circulation* 2004;110:110-118.
- 92) Weltermann A, Eichinger S, Bialonczyk C et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. *Journal of Thrombosis and Haemostasis* 2003;1:28-32.
- 93) Palareti G, Tosetto A, Cosmi B et al. The D-dimer Test to establish the duration of anticoagulation after a first unprovoked episode of venous thrombosis (VTE): the prospective randomized "Prolong" study on behalf of the Italian Federation of Anticoagulant Clinics (FCSA). [abstract]. *Journal of Thrombosis and Haemostasis* 2005;3:H20.
- 94) Stain M, Schonauer V, Minar E et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. *J.Thromb.Haemost.* 2005;3:2671-2676.
- 95) Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis - Incidence and risk factors. *Archives of Internal Medicine* 2000;160:769-774.

Bedeutung der neuen Variante der Creutzfeldt-Jakobschen-Erkrankung in der Transfusionsmedizin

- 1) Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock RD, Jeffrey M, Dawson M, Bradley R. A novel progressive spongiform encephalopathy in cattle. *Vet Rec* 1987;121:419-420
- 2) Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: studies on the epidemiological origin. *Vet Rec* 1991;128:199-203
- 3) Auer F, Blümel J, Burger R, Buschmann A, Dietz K, Heiden M, Hitzler WE, Klamm H, Kreil Th, Kretzschmar H, Nübling M, Offergeld R, Pauli G, Schottstedt V, Seitz R, Volkers P, Zerr I. Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jacob Disease (vCJD). *Transfus Med Hemoth* 2006;33 (suppl 2): 1-39
- 4) Roucou X, LeBlanc AC. Cellular prion protein neuroprotective function: implications in prion diseases. *J Mol Med* 2005;83:3-11
- 5) McBride PA, Schulz-Schaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, Beekes M. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. *J. Virol* 2001;75:9320-9327
- 6) Zou S, Fang CT, Schonberger LB. Transfusion Transmission of Human Prion Diseases. *Transf Med Rev* 2008;22:58-69
- 7) The National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU): Variant Creutzfeldt-Jakob Disease. Current data. www.cjd.ed.ac.uk/vcjdworld.htm.
- 8) Hilton DA, Ghani A, Conyers L, Edwards P, McCardle LM, Ritchie D, Penney M, Hegazy D, Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *J Pathol* 2004;203:733-739
- 9) Ironside JW, Bishop MT, Conolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM, Hilton DA. Variant Creutzfeldt-Jakob disease: Prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. *BMJ* 2006;332:1186-1188
- 10) Hamaguchi T, Noguchi-Shinohara M, Nozaki I, Nakamura Y, Sato T, Kitamoto T, Mizusawa H, Yamada M. Medical procedures and risk for sporadic Creutzfeldt-Jakob disease Japan 1999-2008. *Emerg Infect Dis* 2009;15:265-271
- 11) Dorsey K, Zou S, Schonberger LB, Sullivan M, Kessler D, Notari IV E, Fang CT, Dodd RY. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. *Transfusion* 2009;49:977-984
- 12) Hunter N, Forster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. *J Gen Virol* 2002;83:2897-2905
- 13) Bons N, Lehmann S, Mestre-Frances N, Dormont D, Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to primate *Microcebus murinus*. *Transfusion* 2002;42:513-516
- 14) Herzog C, Sales N, Etcheagaray N, Charbonnier A, Freire S, Dormont D, Deslys JP, Lasmezas CI. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. *Lancet* 2004;363:422-428
- 15) Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. *Haemophilia* 2004;10 (suppl 4):64-69
- 16) Siso S, Gonzales L, Houston F, Hunter N, Martin S, Jeffrey M. The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion. *Blood* 2006;108:745-748
- 17) Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. *Lancet* 2000;356:999-1000
- 18) Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, Siso S, Gonzalez L, Jeffrey M, Hunter N. Prion diseases are efficiently transmitted by blood transfusion in sheep. *Blood* 2008;112:4379-4745
- 19) Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. *Vox Sang* 2006;91:348
- 20) Paul-Ehrlich-Institut. Informationen zu Gerinnungsfaktoren und Prionen. www.pei.de/cln_115/nn_154580/DE/infos/fachkreise/am-infos-ablage/sik/2005-01-02-haemate-info.html?_nnn=true

- 21) Ironside JW. Creutzfeldt-Jakob Disease. *Treatment Hemophilia* 2009;49:1-14
- 22) Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. *Science* 2001;294:1726-1728
- 23) Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, Hilton DA, Ironside JW, Edwards P, McCardle LM, Ritchie DL, Dabaghian R, Ambrose HE, Gill ON. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. *BMJ* 2009;338:b1142
- 24) Alperovitch A, Will RG. Predictiong the size of vCJD epidemic in France. *CR Biol* 2002;325:33-36
- 25) Chadeau-Hyam M, Tard A, Bird S, Le Guennec S, Bemrah N, Volatier JL, Alperovitch A. Estimation of the exposure of the French population to BSE agent: comparison of the 1980-95 consumption of beef products containing mechanically recovered meat in France and the UK, by birth cohort and gender. *Stat Methods Med Res* 2003;12:247-260
- 26) Chadeau-Hyam M, Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France. *Int. J Epidemiol* 2005;34:46-52
- 27) Lefrère JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. *Transfusion* 2009;49:797-812
- 28) Seitz R, Auer F, Blümel J, Burger R, Buschmann A, Dietz K, Heiden M, Hitzler WE, Klamm H, Kreil Th, Kretzschmar H, Nübling M, Offergeld R, Pauli G, Schottstedt V, Volkers P, Zerr I. Impact of vCJD on blood supply. *Biologicals* 2007;35:79-97
- 29) Dietz K, Raddatz G, Wallis J, Mueller N, Zerr I, Duerr HP, Lefèvre H, Siefried E, Loewer J. Blood transfusion and spread of variant Creutzfeldt-Jakob disease. *Emerg Inf Dis* 2007;13:89-96
- 30) Clarke C, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? *J R Soc Interface* 2007;4:675-684
- 31) Garske T, Ward HJT, Clarke P, Will RG, Ghani AC. Factors determining the potential for onward transmission of variant Creutzfeldt-Jakob disease via surgical instruments. *J R Soc Interface* 2006;3:757-766
- 32) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Deutscher Ärzte-Verlag 2007
- 33) Coste J, Prowse C, Eglin R, Fang C. A report on transmissible spongiform encephalopathies and transfusion safety. *Vox Sang* 2009;96:284-291
- 34) Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. *Transfusion Clin Biol* 2006;13:320-328
- 35) Brown P, Rohwer RG, Dunstan BX, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. *Transfusion* 1998;38:810-816
- 36) Stenland CJ, Lee DC, Petteway SR, Rubinstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. *Transfusion* 2002;42:1497-1500
- 37) Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG. Partitioning of TSE infectivity during ethanol fractionation of human plasma. *Biologicals* 2004;32:1-10
- 38) Stellungnahme zum Risiko der Übertragung von vCJK durch Plasmaderivate aus humanem Plasma (Mitteilungen des Arbeitskreises Blut des Bundesministeriums für Gesundheit). *Bgbl* 2009;52:648-649
- 39) Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. *Lancet* 2004;364:529-531
- 40) Prowse C. Prion removal with filter. *ISBT Science Series* 2006;1:230-234.
- 41) Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, Meeker C, Carp R. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. *Vox Sang* 2006;90:265-275

- 42) Beekes M, Blümel J, Burger R, v Dewitz C, Gröner A, Heiden M, Kretzschmar H, Nübling M, Schlenkrich U, Schottstedt V, Seitz R, Strobel J, Willkommen H, Wirsing von König CH, Zerr I. Report of the working group „Overall blood supply strategy with regard to variant Creutzfeldt-Jakob Disease (vCJD)“. *Transfus Med Hemother* 2009;36:79-93
- 43) Castilla J, Saa P, Soto C. Detection of prions in blood. *Nat Med* 2005;11:982-985
- 44) Saa P, Castilla J, Soto C. Presymptomatic detection of Prions in Blood. *Science* 2006;313:92-94
- 45) Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, Caughey B. Ultrasensitive detection of scrapie protein using seed conversion of recombinant prion protein. *Nat Meth* 2007;4:645-650
- 46) Pan T, Li R, Wong BS, Kang SC, Ironside J, Sy MS. Novel antibody enzyme-linked immunosorbent assay that distinguishes prion protein in sporadic and variant cases of Creutzfeldt-Jakob disease. *J Clin Microbiol* 2005;43:1118-1126
- 47) Gregori L, Gray BN, Rose E, Spinner DS, Kascsak RJ, Rohwer RG. A sensitive and quantitative assay for normal PrP in plasma. *J Virol Meth* 2008;149:251-259
- 48) Fagge T, Barclay GR, MacGregor I, Head M, Ironside J, Turner M. Variation in concentration of prion protein in the peripheral blood of patients with variant and sporadic Creutzfeldt-Jakob disease detected by dissociation enhanced lanthanide fluoroimmunoassay and flow cytometry. *Transfusion* 2005;45:504-513
- 49) Varshney M, Waggoner PS, Tan CP, Aubin K, Montagna RA, Craighead HG. Prion protein detection using nanomechanical resonator arrays and secondary mass labelling. *Anal Chem* 2008;80:2141-2148
- 50) Minor P, Newham J, Jones N, Bergeron C, Gregori L, Asher D, van Engelenburg F, Stroebel T, Vey M, Barnard G, Head M. Standards for the assay of Creutzfeldt-Jakob disease specimens. *J Gen Virol* 2004;85:1777-1784
- 51) Cooper JK, Ladhani K, Minor PD. Reference materials for the evaluation of pre-mortem variant Creutzfeldt-Jakob disease diagnostic assays. *Vox Sang* 2007;92:302-310
- 52) Akimov S, Yakovleva O, Vasilyeva I, McKenzie C, Cervenakova L. Persistent propagation of variant Creutzfeldt-Jakob disease agent in murin spleen stromal cell culture with features of mesenchymal stem cells. *J Virol* 2008;82:10959-10962
- 53) v Dewitz C. Legal and ethical aspects regarding the development and application of screening assays to detect vCJD infections. www.karger.com/doi/10.1159/000188082
- 54) Hewitt PE. Implications of notifying donors and recipients. *Vox Sang* 2004;87(suppl 2):S1-S2
- 55) Health Protection Agency, UK. Consultation on a new vCJD test for blood donors. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733832029?p=1225960597236

Gefriergetrocknetes Plasma – Renaissance eines Klassikers

- 1) Querschnittsleitlinien der Bundesärztekammer zur Therapie mit Blutkomponenten und Plasmaderivaten. 4. Auflage 2009.
- 2) Krug EG, Sharma GK, Lozano R. The global burden of injuries. *Am J Public Health* 2000;90:523-526
- 3) Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. *J Trauma* 2003;54:1127-1130.
- 4) Macleod JB, Lynn M, McKenny MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. *J Trauma* 2003;55:39-44.
- 5) Maegele M, Lefering R, Yucel N, Tjardes T, Rixen D, Paffrath T, Simanski C, Neugebauer E, Bouillon B. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. *Injury* 2007;38:298-304
- 6) Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekly AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. *J Trauma* 2007;63:805-813
- 7) Sperry JL, Ochoa JB, Gunn SR, Alarcon LH, Minei JP, Cuschieri J, Rosengart MR, Maier RV, Billiar TR, Peitzman AB, Moore EE; Inflammation the Host Response to Injury Investigators. An FFP:PRBC transfusion ratio $\geq 1:1,5$ is associated with a lower risk of mortality after massive transfusion. *J Trauma* 2008;65:986-993
- 8) Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA, Todd SR, Cocanour CS, Balldin BC, McKinley BA. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. *J Trauma* 2007;62:112-119
- 9) Barrows E. Freeze-dried plasma. The Trail back to the battlefield. *Defense AT&L* 2006;Sept-Oct:16-19
- 10) Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leukocyte alloantibodies in transfusion-related acute lung injury and results of leukocyte antibody screening of blood donors. *Vox Sang* 2008;95:313-317.
- 11) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Deutscher Ärzteverlag 2008
- 12) ICH Richtlinie Q1A(R2) Stability testing of new drug substances and products (CPMP/ICH/2736/99)
- 13) Steil L, Thiele T, Hammer E, Bux J, Kalus M, Völker U, Greinacher A. Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. *Transfusion* 2008;48:2356-2363
- 14) Krutvacho T, Chuansumrit A, Isarangkura P, Pintadit P, Hathirat P, Chiewsilp P. Response to hemophilia A with bleeding to fresh dry plasma. *Southeast Asian J Trop M Public Health* 1993;24:169-173
- 15) Chapanduka ZC, Fernandes-Costa FJTD, Rochat C, Blyth DF. Comparative safety and efficacy Bioplasma FDP versus single-donor fresh-fried plasma in cardiopulmonary bypass patients. *S Afr Med J* 2002;92:34-35
- 16) Shuja F, Shults C, Duggan M, Tabbara M, Butt MU, Fischer TH, Schreiber MA, Tieu B, Holcomb JB, Sondeen JL, deMoya M, Velmahos GC, Alam HB. Development and testing of freeze-dried plasma for the treatment of trauma-associated coagulopathy. *J Trauma* 2008;65:975-985.
- 17) Bender R, Heuter T. Traumaversorgung im Einsatz – ein Fallbericht. *Wehrmedizin und Wehrpharmazie* 2009;2:52-53.
- 18) Pötsch B, Madlener K, Gerinnungskonsil, Thieme-Verlag Stuttgart New York 2002

Der seltene Fall - Versorgung eines Patienten mit einem Anti-Kp(b)

Allan FH, Lewis SJ, Fudenberg H. Studies of anti-Kp(b), a new antibody in the Kell blood group system. *Vox Sang* 1958;3:1-13.

Seltsam A, Wagner FF, Salama A, Flegel WA. Antibodies to high-frequency antigens may decrease the quality of transfusion support: an observational study. *Transfusion* 2003 Nov;43(11):1563-6.

Flegel WA, Von Zabern I, Kroll H, Just B. Rare blood utilization during a 2.5 years observation period in Germany [abstract]. *Vox Sang* 2008;95(Suppl 1):114-115.

Wagner FF, Bittner R, Petershofen EK, Doescher A, Müller TH. Cost-efficient sequence-specific priming-polymerase chain reaction screening for blood donors with rare phenotypes. *Transfusion* 2008 Jun;48(6):1169-73. Epub 2008 Apr 15.